Due to the nature of CAR T cells as living drugs, they display a unique toxicity profile. As CAR T-cell therapy is extending towards other diseases and being more broadly employed in hematology and oncology, optimal management strategies of side-effects associated with CAR T-cell therapy are ...
CAR T cell products were released on all 21 subjects. 86% (18/21) of subjects had a documented minimal residual disease (MRD)-negative complete remission (CR) within 21 days following CAR-T cell therapy. The duration of functional CAR-T cell persistence, as measured by ongoing B-cell ...
LOS ANGELES, April 23 (Xinhua) -- An advance in the breakthrough cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, according to a new study of the University of Southern Californ...
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was see...
A potentially serious side effect has been associated with a new form of immunotherapy called CAR-T cell therapy, recently approved for treating multiple myeloma. Symptoms resembling Parkinson’s disease are a cautionary finding in CAR-T cell treatment for multiple myeloma. ...
An advance in the breakthrough cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, a new USC study shows.
Uses Side effects Warnings Before taking Dosage Interactions FAQ What is Carvykti?Carvykti (ciltacabtagene autoleucel) is a CAR-T therapy used to treat relapsed or refractory multiple myeloma (RRMM). It is an autologous cell therapy, meaning it is made from the patient’s own T cells, ...
Carvykti (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibit...
Yervoy (cancer immunotherapy) Revlimid (blood cancers) Pomalyst (multiple myeloma) Orencia (rheumatoid arthritis) Abecma (CAR-T cell therapy for multiple myeloma) Breyanzi (CAR-T cell therapy for lymphoma) Zeposia (multiple sclerosis) Reblozyl (anemia) Camzyos (heart condition).Opdivo...
Side effects from cancer treatment can affect a patient’s quality of life, but CURE offers its readers content from experts on how to best manage them.